KRAS and lung carcinoma: For instance, in MYCN-amplified but not in non-MYCN-amplified neuroblastoma cell lines, selective silencing of CDK2 leads to apoptosis associated with the upregulation of p53 target genes.310 Similar results were obtained in KRAS-mutated lung cancer, where inhibition of CDK2 results in anaphase catastrophe and apoptosis, reducing the growth of lung cancer xenografts.311